Creative Medical Technology Holdings, Inc. reported a significant operating loss of approximately $6.1 million for the fiscal year ending December 31, 2025, compared to a loss of about $5.7 million in the previous year. The company generated $6,000 in gross revenue, a decrease of 46% from $11,000 in 2024, primarily attributed to a decline in sales of its CaverStem® product. The cost of goods sold also decreased to $2,194 from $4,400, reflecting the reduced revenue. Despite the decrease in revenue, general and administrative expenses rose by 16% to $3.76 million, driven by increased salaries and marketing expenses.
In terms of strategic developments, Creative Medical Technology has made notable advancements in its clinical programs. The company received FDA clearance for its Type I Diabetes (CELZ-201 CREATE-1) clinical trial and the AlloStemSpine® Chronic Lower Back Pain (CELZ-201 ADAPT) trial, with patient recruitment for the latter initiated in September 2023. Additionally, the company has expanded its collaboration with Greenstone Biosciences to develop a human induced pluripotent stem cell (iPSC) pipeline, which is expected to enhance its ImmCelz™ platform. The successful development of this cell line is projected to save the company two to three years in research and development time.
Operationally, the company has focused on enhancing its product offerings and clinical trials. The ImmCelz™ platform has shown promising results, requiring 75% fewer donor patient cells compared to industry standards and achieving a product purity of over 95%. The company also reported a 200% reduction in functional suppression of effector T cells, which is significant for patients with autoimmune issues. As of December 31, 2025, Creative Medical Technology employed four full-time staff members and has not yet commenced commercial activities through its subsidiaries, ImmCelz Inc. and AlloCelz LLC.
Looking ahead, Creative Medical Technology anticipates continued financial losses as it progresses with its clinical trials and product development. The company has indicated that it will need to raise additional capital to support its operations and ongoing research initiatives. As of December 31, 2025, the company had approximately $7.2 million in cash and short-term investments, which it believes will be sufficient to meet its operational needs through at least March 2027. However, the company acknowledges the uncertainty surrounding its ability to achieve profitability and the potential need for further capital raises in the future.
About CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Creative Medical Technology Holdings is a biotech company focused on developing stem cell-based therapies across immunotherapy, endocrinology, urology, neurology, and orthopedics. Its core platforms include reprogrammed immune cells, allogenic stem cell lines, and regenerative procedures for conditions like diabetes, back pain, ovarian failure, and erectile dysfunction. The company leverages proprietary IP, clinical trials, and FDA clearances to advance innovative regenerative treatments targeting multiple diseases and tissue regeneration.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.